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Abstract
Background: Adult invasive pneumococcal disease (IPD) occurs mainly in the elderly and patients with co-morbidities. Little
is known about the clinical characteristics, serotypes and genotypes causing IPD in healthy adults.
Methods: We studied 745 culture-proven cases of IPD in adult patients aged 18–64 years (1996–2010). Patients were
included in two groups: 1.) adults with co-morbidities, and 2.) healthy adults, who had no prior or coincident diagnosis of a
chronic or immunosuppressive underlying disease. Microbiological studies included pneumococcal serotyping and
genotyping.
Results: Of 745 IPD episodes, 525 (70%) occurred in patients with co-morbidities and 220 (30%) in healthy adults. The
healthy adults with IPD were often smokers (56%) or alcohol abusers (18%). As compared to patients with co-morbidities,
the healthy adults had (P,0.05): younger age (43.5+/213.1 vs. 48.7+/211.3 years); higher proportions of women (45% vs.
24%), pneumonia with empyema (15% vs. 7%) and infection with non-PCV7 serotypes including serotypes 1 (25% vs. 5%),
7F (13% vs. 4%), and 5 (7% vs. 2%); and lower mortality (5% vs. 20%). Empyema was more frequently caused by serotype 1.
No death occurred among 79 patients with serotype 1 IPD. There was an emergence of virulent clonal-types Sweden1-ST306
and Netherlands7F-ST191. The vaccine serotype coverage with the PCV13 was higher in healthy adults than in patients with
co-morbidities: 82% and 56%, respectively, P,0.001.
Conclusion: In this clinical study, one-third of adults with IPD had no underlying chronic or immunosuppressive diseases
(healthy adults). They were often smokers and alcohol abusers, and frequently presents with pneumonia and empyema
caused by virulent clones of non-PCV7 serotypes such as the Sweden1-ST306. Thus, implementing tobacco and alcohol
abuse-cessation measures and a proper pneumococcal vaccination, such as PCV13 policy, in active smokers and alcohol
abusers may diminish the burden of IPD in adults.
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Introduction
Streptococcus pneumoniae remains a major cause of morbidity and
mortality worldwide. The pneumococcus, with more than 93
serotypes, usually colonizes the nasopharynx of young children,
and more infrequently of adults, and occasionally can invade the
lungs, bloodstream or brain causing severe infections [1–7].
Invasive pneumococcal disease (IPD) occurs mainly in young
children and older adults ($65years) as well as in patients with co-
morbidities (e.g., chronic lung disease, cardiovascular disease,
cirrhosis, malignancies, HIV, asplenia) [5,6]. Although several
case reports exist, little is known about the characteristics of IPD in
healthy adults [6]. Some reports have also shown that young
people who are smokers or alcohol abusers may be at higher risk of
IPD [5,8].
The prevention of adult IPD has been based on the
pneumococcal polysaccharide vaccine 23-valent (PPV23), which
is recommended for the elderly and patients with co-morbidities
[9]. However, its immunologic response and effectiveness may not
be optimal in some populations, particularly in immunocompro-
mised patients [10]. The 7-valent pneumococcal conjugate vaccine
(PCV7), which usually produces a better immunologic response
and may reduce acquisition of nasopharyngeal carriage, was
introduced in the year 2000 for children in the USA [11] and it
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was followed by a decline in IPD caused by vaccine serotypes in
children as well as in adults - through an indirect effect (herd
protection) - [11,12]. The recent introduction of the PCV10 and
PCV13 for children and currently for adults may change
significantly the IPD epidemiology. However, the consequences
of the ‘‘replacement phenomenon’’, -that means the emergence of
serotypes not contained in the conjugate vaccines- [13,14], are
unknown.
Thus, it is important to know the serotypes causing IPD,
including in healthy adults, in order to look for new target
populations for implementing future vaccination strategies.
The objectives of our study were to analyze the clinical
presentation, serotypes and clonal-type distribution, and mortality
of IPD in healthy adults (aged 18–64 years).
Methods
We have collected data on all patients with IPD at our
institution (Hospital Bellvitge, University of Barcelona) over the
past three decades. A detailed description of the methodology was
reported elsewhere [15–17].
For the present report, we studied all IPD episodes seen during
the last 15 years (1/1996–12/2010) in adults aged 18–64 years.
Patients were included in two groups: ‘‘healthy adults’’ and
‘‘patients with co-morbidities’’.
Definitions
Culture-proven IPD was defined according to the clinical
findings and the isolation of Streptococcus pneumoniae from a normally
sterile body fluid such as blood, pleural fluid, cerebrospinal fluid
(CSF), peritoneal fluid or joint fluid. Pneumococcal pneumonia
was diagnosed in patients with signs or symptoms of an acute
lower respiratory tract infection together with a new pulmonary
infiltrate on chest radiograph. For the diagnosis of empyema,
isolation of S.pneumoniae from the pleural fluid was required. Other
origins of IPD (e.g., meningitis, peritonitis, arthritis) were
diagnosed based on standard criteria.
Alcohol abuse was considered when the patient reported a daily
alcohol intake of 80 gr. or 60 gr. for men and women,
respectively, at least during the previous year. Current smoking
was considered when the patient has been smoking at least ten
cigarettes per day during the last year. It should be in mind that
self reporting of alcohol and smoking habits is notoriously
unreliable, and tend to underestimate consumption.
Special care was taken in assessing smokers and alcohol abusers
to rule out associated co-morbidities. Prior antibiotic therapy was
defined as the intake of any antibiotic for more than 48 hours
during the previous 3 months.
We considered patients to be ‘‘healthy adults’’ when they had
no prior or coincident diagnosis of a chronic or immunosuppres-
sive underlying disease. Otherwise, ‘‘patients with co-morbidities’’
were those who had a confirmed diagnosis of one or more of the
following: chronic pulmonary diseases (e.g., chronic obstructive
pulmonary disease [COPD], emphysema, bronchiectasis, asthma,
interstitial lung disease); cardiovascular diseases, chronic liver
disease, diabetes, malignant disease, HIV infection, chronic
rheumatic diseases or vasculitis, end stage chronic renal failure,
cerebrovascular or degenerative brain diseases, asplenia, trans-
plant recipients (bone marrow and solid-organ transplants), and
long-term use of corticosteroids or other immunosuppressive
therapies.
The diagnosis of septic shock was based on a systolic blood
pressure below 90 mm Hg and peripheral hypoperfusion together
with clinical and/or bacteriological evidence of uncontrolled
infection. Antibiotic therapy was prescribed according to the
hospital guidelines being the most frequent schedules for
pneumonia: ceftriaxone, levofloxacin or macrolides, alone or in
combination; and for meningitis: cefotaxime with or without
vancomycin. Mortality was recorded when the patient died within
30 days of diagnosis.
Ethical statement. This study and publication of the results were
approved by the ‘‘Institutional Review Board - Comite´ E`tic
d’Investigacio´ Clı´nica del Hospital Universitari de Bellvitge’’, and
the Institutional Review Board specifically waived the need for
consent because the study was retrospective and the source of data
was anonymized.
Microbiological methods
Streptococcus pneumoniae strains were identified by conventional
methods (optochin susceptibility and bile solubility). Pneumococci
were serotyped by dot-blot assay or Quellung reaction at the
Spanish Reference Laboratory, Majadahonda, Madrid, Spain.
We evaluated the vaccine serotype coverage of PCV7 (serotypes
4, 6B, 9V, 14, 18C, 19F, 23F), PCV10 (additional 1, 5, 7F) and
PCV13 (additional 3, 6A, 19A). In Spain, pneumococcal
conjugate vaccines for children were introduced as follows:
PCV7 in June 2001, PCV10 in May 2009 and PCV13 in June
2010.
Antimicrobial susceptibility to penicillin, cefotaxime, ceftria-
xone, erythromycin, tetracycline, ciprofloxacin and co-trimoxazole
were tested by microdilution method (Sensititre) following the
Clinical Laboratory Standard Institute (CLSI) methods [18]. S.
pneumoniae ATCC 6303 and S. pneumoniae ATCC 49619 were used
as control strains. Antimicrobial resistances were determined
according to the CLSI criteria [19].
Pulsed-field-gel-electrophoresis (PFGE) was performed to all
available isolates. Genomic DNA embedded in agarose plugs was
restricted with SmaI (New England BioLabs) and fragments were
separated by PFGE in a CHEF-DRIII apparatus (Bio-Rad).
Multilocus sequence typing (MLST) was carried out as described
previously [20] on selected strains that were representative isolates
of PFGE clusters shared by three or more isolates. The allelic
number and sequence types (ST) were assigned using the
pneumococcal MLST web site http://spneumoniae.mlst.net/,
which is located at Imperial College London and is funded by
the Wellcome Trust. When an unusual association between
serotype and sequence type was found, the serotype was confirmed
by PCR, using previously described methodology (http://www.
cdc.gov/ncidod/biotech/strep/pcr.htm), and MLST was repeat-
ed.
Statistical analysis
Statistical analysis was carried out with the PASW-18. We used
Chi-square test or Fisher’s exact test for categorical variables (two-
by-k contingency tables) and Student t test for continuous
variables. Analyses were adjusted by means of multiple logistic
regression models in order to determine those variables indepen-
dently associated with healthy adults (compared to patients with
co-morbidities). All P values were two-tailed and P,0.05 were
considered statistically significant. To calculate the incidence rates
we used as a denominator the number of persons, by age group
per year, in the public database of the Web ‘‘Official Statistics in
Catalonia’’ [21].
Results
Between 1/1996 and 12/2010, we studied 1414 IPD episodes in
adult patients, in whom S.pneumoniae was isolated from one or more
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sterile site: blood 1320, pleural fluid 128, CSF 107, abdominal
fluid 68, and joint fluid 2.
Out of 1414 IPD episodes, 745 (53%) occurred in adults (aged
18–64 years) and 669 (47%) in elderly ($65 years). Out of 745 IPD
episodes in adults, 525 (70%) occurred in patients with co-
morbidities and 220 (30%) in healthy adults. The co-morbidities
diagnosed in our patients are shown at the foot of Table 1.
The incidence rates of IPD among adults (aged 18–64 years) in
three periods (1996–2000 vs. 2001–2005 vs. 2006–2010) and
according to PCV7 serotypes/non-PCV7 serotypes were: 3.5/5.0
vs. 2.9/6.8 vs. 2.5/9.2 episodes/100.000 (P,0.001) respectively.
Also, over the study period the proportion of IPD episodes in
healthy adults increased: 18% (35/193) vs. 32% (78/245) vs. 35%
(107/307), P,0.001.
There was an increase in non-PCV7 serotypes (periods: 1996–
2000 vs. 2001–2005 vs. 2006–2010) among healthy adults: 66%
(23/35) vs. 82% (64/78) vs. 86% (89/103), P = 0.02; and among
patients with comorbidities: 57% (89/156) vs. 64% (106/165) vs.
75% (144/192), P = 0.002.
Characteristics of healthy adults
As shown in Table 1, compared to patients with co-morbidities,
the healthy adults had: younger age and higher proportion of
women; more frequently pneumonia with empyema; and lower
proportions of alcohol abusers, prior antibiotics, shock and
mortality. The healthy adults also had lower antibiotic resistance
rates.
Of note, the healthy adults with IPD were often smokers (56%)
or alcohol abusers (18%), and when stratified by gender and age
group (18–49 and 50–64 years) these percentages were: smokers
(men, 73% and 48%; women, 59% and 28%); and alcohol abusers
(men, 25% and 38%; women, 4% and 4%), Figure 1.
In the subgroup of 549 patients with pneumonia, healthy adults
(compared to patients with co-morbidities) had: higher proportion
of empyema 18% (33/182) vs.10% (36/367), P = 0.006; and lower
proportions of multilobar pneumonia 23% (42/182) vs. 34% (123/
367), P = 0.011, and respiratory failure 34% (61/182) vs. 52%
(192/367), P,0.001.
Healthy adults (compared to patients with co-morbidities) had
higher proportions of serotypes 1,7F and 5, and lower proportions
of serotype 19F, 23F and others (Table 2). The distribution of
serotypes in more recent years (period 2006–2010) is shown in
Table 1. Characteristics of 745 invasive pneumococcal disease episodes in adults (aged 18–64 years): A comparison between
patients with co-morbidities and healthy adults.
Healthy N=220 Co-morbidities* N=525 P Value
Age, mean+/2SD, years 43.53 (+/213.1) 48.78 (+/211.3) ,0.001
18–49 yrs 134 (61) 257 (49) 0.003
50–64 yrs 86 (39) 268 (51)
Sex
Female 99 (45) 124 (24) ,0.001
Male 121 (55) 401 (76)
Alcohol abuse 39 (18) 130 (25) 0.030
Current smoking 123 (56) 304 (58) 0.530
Prior antibiotic therapy 18 (8) 182 (35) ,0.001
Clinical syndromes
Pneumonia with empyema 33 (15) 36 (7) ,0.001
Pneumonia without empyema 149 (68) 331 (63)
Others{ 38 (17) 158 (30)
Shock at presentation 15 (7) 107 (20) ,0.001
30-day mortality 11 (5) 107 (20) ,0.001
Antibiotic Resistance{
Penicillin
Non-meningeal (MIC$4 mg/mL) 4 (2) 12 (2) 0.688
Meningeal (MIC$0.12 mg/mL) 36 (16) 180 (34) ,0.001
Cefotaxime/Ceftriaxone
Non-meningeal (MIC$2 mg/mL) 4 (2) 10 (2) 0.937
Meningeal (MIC$1 mg/mL) 17 (8) 81 (15) 0.011
Erythromycin (MIC$0.5 mg/mL) 33 (15) 124 (24) 0.009
Unless otherwise indicated, data are reported as number (percentage). MIC denotes minimum inhibitory concentration.
*Co-morbidities (some patients had more than one): HIV infection (n = 159), malignant disease (n = 143), chronic liver disease (n = 131), immunosuppressive therapy
(n = 128), diabetes (n = 92), chronic pulmonary disease (n = 82), cardiovascular diseases (n = 45), transplant recipients (n = 29), chronic rheumatic disease or vasculitis
(n = 20), asplenia (n = 19), end stage renal failure (n = 17), cerebrovascular diseases/degenerative brain diseases (n = 7).
{Other clinical syndromes [healthy (n) vs. co-morbidities (n)]: primary bacteraemia (3 vs. 42), meningitis (27 vs. 37), spontaneous bacterial peritonitis (0 vs. 50),
abdominal/biliary tract (2 vs. 11), soft tissue infections (0 vs. 7); endocarditis (3 vs. 0); osteoarticular (2 vs. 5); otitis/sinusitis (1 vs. 6).
{According to the new Clinical Laboratory Standard Institute breakpoints. Resistance to other antibiotics (healthy vs. co-morbidities): tetracycline (12% vs. 26%); co-
trimoxazole (20% vs. 41%) and ciprofloxacin (0.5% vs. 1%).
doi:10.1371/journal.pone.0042595.t001
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Figure 2. The vaccine serotype coverage (2006–2010) was higher
in healthy adults than in patients with co-morbidities for PCV13
(82% vs. 56%, P,0.001) and for PCV10 (63% vs. 35%, P,0.001),
while it was lower for PCV7 (14% vs. 25%, P = 0.022).
Of 79 serotype 1 isolates, 72 were genotyped, which were
included into two genotypes related to ST304 (N = 15, Sweden1-
ST304) and ST306 (N = 57, Sweden1-ST306). There was an
emergence of ST306 during the study period: 43% (6/18 isolates)
in 1996–2000, 91% (21/23) in 2001–2005 and 86% (30/35) in
2006–2010 (P = 0.001). Of 49 serotype 7F isolates, 48 were
genotyped and shared a common genotype related to ST191
(Netherlands7F-ST191 clone). Of 25 serotype 5 isolates, 22 were
genotyped and shared a common PFGE type related to
Columbia5-ST289 clone and associated with two STs (ST289
and ST1223).
Multivariate analyses
Tables 1 and 2 show the clinical characteristics of IPD and
serotypes. In a multiple logistic regression model, those variables
independently associated with healthy adults (compared to patients
with co-morbidities) were: younger age (#49 yrs) [OR = 1.85,
95%CI 1.29–2.65, P = 0.001], female sex [OR = 2.56, 95%CI
1.76–3.72, P,0.001], presentation with pneumonia plus empy-
ema [OR = 2.14, 95%CI 1.19–3.85, P = 0.010], serotype 1
[OR = 6.86, 95%CI 3.99–11.81, P,0.001], serotype 5
[OR = 5.53, 95%CI 2.33–13.11, P,0.001], and serotype 7F
[OR = 3.82, 95%CI 2.04–7.13, P,0.001].
Mortality
As expected, the healthy adults with IPD had a lower mortality
rate than patients with co-morbidities (Table 1), and this persisted
significantly lower after adjustment for age, gender, clinical
presentation and serotypes (adjusted OR = 0.31, 95%CI 0.16–
0.62, P = 0.001).
Of note, no deaths occurred among the 79 patients with
serotype 1 IPD. However, 12% (6/49) of patients with serotype 7F
and 8% (2/25) of patients with serotype 5, died.
Figure 1. Percentage of current smokers and alcohol abusers among 220 healthy adults with invasive pneumococcal disease.
doi:10.1371/journal.pone.0042595.g001
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Table 3 shows the 11 healthy adults with IPD who died. Early
death occurred in 4 patients (2 with fulminant sepsis and 2 with
meningitis). Two patients with endocarditis, without underlying
cardiac disease, had a history of alcohol abuse and one of them
died because of complications of cardiac surgery and the other due
to a nosocomial infection. A 19-year old boy who presented with
progressive bilateral pneumonia caused by serotype 3 died. The
remaining 4 patients had extensive bacteremic pneumonia caused
by serotypes 14 or 7F. In all cases the pneumococcal isolates were
susceptible to the antibiotics administered.
Pneumonia and empyema
Among 549 patients with pneumonia, 69 (13%) had associated
empyema with isolation of S.pneumoniae in pleural fluid (‘‘empyema
group’’), and 480 (87%) had pneumonia without empyema
(‘‘pneumonia group’’) (Table 4).
Empyema occurred more frequently in healthy adults and was
often associated with serotype 1, particularly the clonal-type
Sweden1-ST306 (15 of 17 cases).
Discussion
In our study, about one third of adults (aged 18–64 years) with
IPD were healthy, and we observed an increase in IPD caused by
non-PCV7 serotypes, particularly the serotypes 1, 7F and 5. Of
special concern has been the spread of some specific clonal-types,
such as Sweden1-ST306 of serotype 1 that was strongly associated
with empyema.
Our findings are consistent with some reports considering
serotypes 1, 5 and 7F as primary pathogens with a high invasive
disease potential, because they often cause IPD in children but are
associated with a brief duration of colonization and are rarely
found in the nasopharynx. [22–25]. The serotype 1 clone
(Sweden1-ST306) seen in our study was first identified in Sweden
in 1990’s with a subsequent spread to other European countries
[24,26–31].
Smokers and alcohol abusers are at greater risk for IPD [5,8].
Indeed, our healthy adults with IPD were frequently smokers or
alcohol abusers; and we decided not to exclude them from the
healthy adults group in order to identify factors suitable for future
vaccination strategies. Thus, our results suggest that avoiding
smoking and alcohol abuse and reinforcing the pneumococcal
vaccination (CDC recommendations) for active smokers and
alcohol abusers [9] may reduce the IPD rates in adults. These data
support the initiative of Joint Commission’s tobacco-cessation
interventions in patients attending health care visits [32].
The increased proportion of women among our healthy adults
with IPD may reflect that healthy women have often contact with
Figure 2. Serotype distribution among 295 pneumococcal isolates causing adult IPD in more recent years (period 2006–2010).
doi:10.1371/journal.pone.0042595.g002
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children who may facilitate the transmission of the pneumococcus
and that they often had a history of smoking which may predispose
to IPD.
Pneumococcal strains often harbour antibiotic resistance
[15,33,34]. Our healthy adults had lower antibiotic resistance
rates than patients with co-morbidities (Table 1) since they were
often infected with susceptible serotypes and received prior
antibiotics less frequently. Most non-meningeal pneumococcal
isolates were penicillin-, and ceftriaxone-susceptible, which sup-
port the use of these classic beta-lactams in the treatment of
pneumococcal infections [15,33].
Occasionally, we have seen healthy adults with IPD who died
despite appropriate antibiotic therapy. It should be noted that few
of them were alcohol abusers but several others denied alcohol
abuse and presented with severe clinical syndromes (Table 3). It is
possible that unknown underlying host factors or increased
virulence of some serotypes or clonal-types may have played a
role in the patient’s death.
An important finding of our study is the high prevalence of
serotype 1 in healthy adults, particularly the clonal-type Sweden1-
ST306, which was strongly associated with empyema, as occurred
in older children [27,28]. The intrinsic characteristics of serotype 1
capsular polysaccharide structure, surface proteins properties or
the pneumolysin might explain some differences in the clinical
presentation [25,35].
Also, it is unknown why serotype 1 is more prevalent in older
children and healthy adults than in patients with co-morbidities. We
can speculate that patients with co-morbidities, who often undergo
antibiotic pressure and may have local and systemic immunodefi-
ciencies, are more predisposed to be colonized/infected with multi-
resistant serotypes -with low invasive disease potential- such as 19F
and 23F, and because of a phenomenon of ‘‘competition among
serotypes in the nasopharyngeal niche’’ they could be less
predisposed to acquire other serotypes such as serotype 1. On the
contrary, healthy adults who are not usually nasopharyngeal
carriers could be more predisposed to be infected with invasive
serotypes, which act as primary pathogens, such as serotype 1.
Some reports have shown a low mortality of serotype 1 IPD
[36,37]. Interestingly, none of our 79 patients with IPD caused by
serotype 1 died, which may be related to host’s characteristic (e.g.,
healthy people) or differences in pneumococcal-dependent factors
(e.g., capacity to generate a host inflammatory response) [25].
It is well known the widely geographical variation of serotype 1,
which is quite prevalent in several European countries but less
common in USA and Canada [25]. Also, several epidemics of
serotype 1 IPD have been reported in South American, Asian and
African countries [25,38]. It is possible that genetic and
environmental factors as well as clonal-type dissemination may
explain some of these differences. For example, cases of serotype 1
IPD reported in USA were often caused by a different clonal-type,
the ST227 [39].
We also found a high prevalence of serotypes 7F and 5 among
healthy adults. The characteristics of IPD caused by these
serotypes were quite similar to those of serotype 1, except that
were less strongly associated with empyema and some of them
died. Serotype 3 was also prevalent in healthy adults as well as in
patients with co-morbidities (Table 2).
We found that the serotype coverage of the recently introduced
PCV13 was higher in healthy adults than in patients with co-
morbidities, which reflects a different serotype distribution. We do
not know if in areas with increased prevalence of serotype 1 (which
affects more frequently older children and healthy adults), the use
of PCV13 for children ,2 yrs will be associated with a decline of
IPD in healthy adults (by herd protection). Recent studies have
evaluated the cost-effectiveness of PCV13 compared to PPV23 in
adult vaccination, and suggest an advantage of the PCV13 with
the assumption that it would be effective against non-bacteremic
pneumococcal pneumonia [40].
Although our study refers to a large cohort of patients with IPD,
it may have some limitations: 1) the study was performed in
Barcelona and these results may not be entirely extrapolated to
other geographical areas; 2) our study did not show specific
incidence rates of IPD in healthy people and in patients with co-
morbidities since we do not know these denominators; and 3) we
could not investigate other possible risk factors for IPD such as
viral co-infections, nor the close contact with young children.
In conclusion, our study shows that IPD often occurs in healthy
adults, particularly smokers and alcohol abusers, and frequently
presents with pneumonia and empyema associated with virulent
clones of non-PCV7 serotypes. Thus, implementing tobacco and
alcohol abuse-cessation measures and a proper pneumococcal
vaccination, which may include a broader spectrum conjugate
vaccines such as PCV13, in active smoker and alcohol abusers
may diminish the burden of IPD in adults.
Table 2. Serotype distribution among 745 invasive
pneumococcal isolates from adults (healthy vs. co-
morbidities).
Serogroups
/serotypes Healthy N=216*
Co-morbidities
N=513* P value
n6 strains (%)
1 55 (25) 24 (5) ,0.001
3 21 (10) 33 (6) 0.121
4 11 (5) 25 (5) 0.901
5 15 (7) 10 (2) 0.001
6A 5 (2) 12 (2) 0.984
6B 2 (1) 11 (2) 0.364
6C 1 (0.5) 8 (2) 0.458
7F 27 (13) 22 (4) ,0.001
8 7 (3) 20 (4) 0.668
9N 0 11 (2) -
9V 7 (3) 30 (6) 0.143
11A 4 (2) 14 (3) 0.607
12 7 (3) 17 (3) 0.960
14 12 (6) 37 (7) 0.415
18C 3 (1) 14 (3) 0.420
19A 12 (6) 37 (7) 0.415
19F 3 (1) 30 (6) 0.006
23A 0 11 (2) -
23F 2 (1) 27 (5) 0.006
Others{ 22 (10) 120 (23) ,0.001
*A total of 745 IPD episodes. Out of 220 IPD in healthy adults, 216 (98%) were
serotyped. Out of 525 IPD in patients with co-morbidities, 513 (98%) were
serotyped.
{Others [healthy (n) vs. co-morbidities (n)]: 10A (2 vs. 10), 13 (0 vs. 3), 15A (3 vs.
9), 15B (0 vs. 9), 15C (0 vs. 3), 15F (0 vs. 4), 16F (0 vs 5), 17 (0 vs. 5), 18A (0 vs. 1),
18B (0 vs. 1) 20 (0 vs. 10), 21 (0 vs. 1), 22F (5 vs. 8), 23B (2 vs. 2), 24F (2 vs. 8), 25 (2
vs. 1), 28 (0 vs. 2), 29 (0 vs. 2), 31 (0 vs. 5), 32 (0 vs. 1), 33 (3 vs. 4), 34 (0 vs. 7), 35
(1 vs. 13), 37 (0 vs. 1), 38 (0 vs. 2), 48 (0 vs. 1), non-typable (2 vs. 2).
doi:10.1371/journal.pone.0042595.t002
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Table 4. Pneumococcal pneumonia in 549 adults: A comparison between patients with pneumonia and empyema (Empyema
group) and those with pneumonia without empyema (Pneumonia group).
Empyema group N=69 Pneumonia group N=480 P
Age, mean+/2SD, years 46.83 (+/212.83) 46.74 (+/212.23) 0.959
18–49 yrs 33 (48) 261 (54) 0.308
50–64 yrs 36 (52) 219 (46)
Sex
Female 21 (30) 146 (30) 0.998
Male 48 (70) 334 (70)
Underlying diseases
Healthy 33 (48) 149 (31) 0.006
Co-morbidities* 36 (52) 331 (69)
Alcohol abuse 13 (19) 115 (24) 0.347
Current smoking 40 (58) 301 (63) 0.448
Multilobar pneumonia 20 (29) 145 (30) 0.968
Respiratory failure 33 (48) 220 (46) 0.827
Shock at presentation 7 (10) 88 (18) 0.060
30-day mortality 6 (9) 71 (15) 0.198
Serotypes{
Serotype 1 17 (25) 56 (12) 0.003
Serotype 3 8 (12) 35 (7) 0.162
Serotype 7F 4 (6) 41 (9) 0.320
Others 39 (57) 340 (72) 0.013
Unless otherwise indicated, data are reported as number (percentage).
*Co-morbidities in the empyema group (n) vs. pneumonia group (n) (some patients had more than one): HIV infection (9 vs. 116), malignant disease (15 vs. 85), chronic
liver disease (4 vs. 55), immunosuppressive therapy (11 vs. 78), diabetes (5 vs. 57), chronic pulmonary disease (7 vs. 62), cardiovascular disease (2 vs. 33), chronic
rheumatic disease or vasculitis (0 vs. 15), asplenia (1 vs. 3), end stage renal failure (3 vs. 12), transplant recipients (1 vs. 17), cerebrovascular or degenerative brain disease
(1 vs. 5).
{The most common serotypes in patients of empyema group (68/69 serotyped) were: serotype 1 (25%), 3 (12%), 7F (6%), 5 (4%), 19A (4%), 19F (4%), 23F (4%), 4 (3%), 6A
(3%), 6B (3%), 8 (3%), 9V (3%), 18C (3%), 23A (3%) and 22 (3%).
The most common serotypes in patients of pneumonia group (472/480 serotyped) were: serotype 1 (12%), 7F (9%), 14 (8%), 19A (8%), 3 (7%), 4 (6%), 9V (5%), 5 (5%), 8
(5%), 12F (4%), 23F (3%), 11A (3%), 18C (3%) and 19F (2%).
doi:10.1371/journal.pone.0042595.t004
Table 3. Summary of the 11 healthy adults with invasive pneumococcal disease who died.
Patient
Sex/Age
(yr)
Alcohol
abuse
Current
smoking
Clinical
syndrome
Source of
isolate
Shock at
presentation
Antibiotic
therapy
Days to
death Serotype
1 M/52 Yes Yes Endocarditis/
Meningitis
blood No CTX 29 10A
2 M/42 Yes Yes Endocarditis blood Yes CRO 16 4
3 M/19 No Yes Pneumonia blood Yes CRO 9 3
4 F/53 No No Pneumonia blood No CRO+LEVO 30 14
5 F/58 No No Pneumonia blood Yes CRO 29 7F
6 M/49 Yes No Pneumonia blood No LEVO 10 14
7 M/36 No No Sepsis blood Yes CRO 1 6A
8 F/40 No Yes Pneumonia blood Yes CRO 12 7F
9 M/37 No No Meningitis Blood/CSF No VAN+RIFA 4 3
10 M/39 No Yes Sepsis blood Yes CTX 1 ND
11 M/59 No Yes Meningitis Blood/CSF Yes CTX 3 3
Abbreviations: M, male; F, female; CTX, cefotaxime; CRO, ceftriaxone; LEVO, levofloxacin; VAN, vancomycin; RIFA, rifampin; ND, not done.
doi:10.1371/journal.pone.0042595.t003
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